Dr. Bernard Zinman — The Samuel Lunenfeld Research Institute

Personal tools

You are here: Home → Researchers → Dr. Bernard Zinman

Dr. Bernard Zinman
SENIOR INVESTIGATOR

Dr. Bernard Zinman, a clinician-scientist at Mount Sinai, is a recognized leader in the field of diabetes. His research focuses on the prevention of the long-term complications of diabetes, new treatments for diabetes, and diabetes in high-risk populations. His research holds promise for increased understanding of how to deal with this growing, global epidemic.

For more than 25 years, Dr. Zinman has played a key role in the Diabetes Control and Complications Trial, the largest and most comprehensive diabetes complications study ever conducted in Type 1 diabetes. This pivotal study demonstrated that keeping blood glucose levels as close to normal as possible slows the onset and progression of eye, kidney, and nerve complications caused by diabetes. One of the most cited diabetes study in the world, this study had a global impact on treatment of Type 1 diabetes patients and the occurrence of complications.

Dr. Zinman is Director of the Leadership Sinai Centre for Diabetes, a unique, multi-disciplinary outpatient unit that is one of the largest diabetes clinical research units in Ontario. Under his leadership, the Centre provides the highest quality care by integrating clinical practice, research and education for those with diabetes and their families.

Samuel Lunenfeld Research Institute
Mount Sinai Hospital
Joseph & Wolf Lebovic Health Complex
600 University Avenue
Toronto Ontario M5G 1X5
Tel: 416-586-4800 ext.8747
Send Email

Jul 15, 2009 05:05 PM

At a Glance

Dr. Bernard Zinman is a clinician-scientist whose research interests include both type 1 and type 2 diabetes
His team focuses on the long-term complications of diabetes, evaluating new therapies, and diabetes in Aboriginal communities

Major Research Activities

Dr. Zinman’s research interests include both type 1 and type 2 diabetes. His research team focuses on three areas: the long-term complications of diabetes, evaluation of new therapies, understanding the underlying causes of type 2 diabetes in Aboriginal communities. Since 1992, Dr. Zinman and his collaborators have been examining the prevalence of diabetes and its associated risk factors in Sandy Lake, an isolated native community located in the Sioux Lookout Zone of northwestern Ontario.

Recent Publications

Feig D, Zinman B, Wang X, Hux JE. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. Canadian Medical Association Journal 179(3):229-234, July 2008.

Retnakaran R, Qi Y, Sermer M, Connelly PW, Hanley AJ, Zinman B. The antepartum glucose values that predict neonatal macrosomia differ from those that predict postpartum pre-diabetes or diabetes: implications for the diagnostic criteria for gestational diabetes. J Clin Endocrinol Metab 94(3): 840-845, March 2009

Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the ADA and the EASD for the study of diabetes. Diabetes Care 32(1): 193-203, January 2009.
Cherney D, Konvalinka A, Zinman B, Diamandis EP, Soosaipillai A, Reich H, Lorraine J, Lai V, Scholey JW, Miller JA. Effect of protein kinase Cß inhibition on renal hemodynamic function and urinary biomarkers in humans with Type 2 diabetes: A pilot study. Diabetes Care 32(1): 91-93, January 2009.

Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R. Renal and retinal effects of Enalapril and Losartan in Type 1 diabetes. NEJM 361: 40-511, 2009.

Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ for the DCCT/EDIC Research Group. Modern-day clinical course of Type 1 diabetes mellitus after 30 years' duration. Arch Int Med 169(14): 1307-1316, 2009.

Personal tools

Document Actions